ArticleCNS & neurological disorders drug targets2026
Putative Antianxiety Property of Oral Enalapril Formulation in Mice: a Preclinical and
Article in CNS & neurological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnxiety disorders, characterized by overwhelming fear, affect more than 30% of the global population. Recent evidence indicates that antihypertensive medications could offer symptomatic relief for anxiety, supporting their potential for repurposing. The objective is to investigate the anxiolytic-like effects of an enalapril formulation.
methods60 Swiss mice (30 ± 5 g, aged 6-8 weeks) were randomly assigned to groups and received oral treatments with either vehicle (10 mL/kg), diazepam (DZP, 5 mg/kg), reference enalapril (ENAR), enalapril formulation (ENAF), losartan (LOS), or propranolol (PRO), each at a dose of 10 mg/kg. After 60 minutes, the animals were exposed to 5 minutes of exploratory activity in the open field, elevated plus maze (EPM), light-dark box (LDB), and a minute of rotarod.
resultsOne-way ANOVA demonstrated differences for the total crossing (p=0.0001), freezing time (p=0.0001), number of rearing (p=0.002), time spent (p=0.002), and crossing at the center (p=0.0001) of the open field. Unlike in the rotarod (p>0.05), the ENAR, ENAF, LOS, and PRO elicit increases (p<0.05) in the total number of arm entries and time spent on the open arms of EPM while increasing the number of transitions (p<0.05) and time spent in the light area of the LDB (p=0.001). In silico screening suggests stability of interaction with several amino acid residues overlapping with the flumazenil binding site, with the binding energy (ΔE) = -22.59kcal/mol towards the benzodiazepine binding site (flumazenil ΔE = -43.92kcal/mol). DISCUSSION: The repositioning of drugs available to the population is an interesting approach toward the discovery of alternative or add-on treatments for anxiety. Ongoing resort to repurposing, reusing, reprofiling, and rediscovery of "old" drugs for a new indication seems to be an interesting way out of failures, the expensive and slow pace of new drug discovery.
conclusionEnalapril demonstrates anxiolytic-like properties, further insights into the GABAergicrenin- angiotensin-aldosterone mechanistic hypothesis.
Indexed as
Identifiers
41589494What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.